



## ENDOCEUTICS, INC. ANNOUNCES INITIATION OF THE SALE AND INVESTMENT SOLICITATION PROCESS

**Québec, Canada:** – January 4, 2023: On September 26, 2022, Endoceutics, Inc. and its subsidiaries (together, the “**Companies**” or “**Endoceutics Group**”) were granted protection pursuant to an order (as amended or amended and restated from time to time, the “**Initial Order**”) under the *Companies’ Creditors Arrangement Act* (the “**CCAA**” and the “**CCAA Proceedings**”) by the Superior Court of Québec (the “**Court**”). EY was appointed as monitor (in such capacity, the “**Monitor**”).

On December 7, 2022, the Court issued an order (the “**SISP Order**”), authorizing the Monitor, in consultation with the Endoceutics Group and its senior secured creditor, CRG Servicing LLC, to conduct a sale and investment solicitation process (the “**SISP**”). The SISP involves the solicitation of interest in an acquisition of the Companies or a sale of all, substantially all or one or more components of the Companies’ assets by way of an asset sale, merger, reorganization, recapitalization, primary equity issuance or other similar transaction as a going concern or otherwise (the “**Opportunity**”).

The SISP is a two-phased process with the Phase 1 bid deadline set for February 17, 2023. Parties interested in the Opportunity should contact the Monitor via one of the persons listed below to get further details.

Jatinder Wadhwa  
Senior Vice President  
416 943 3078  
[jatinder.wadhwa@ca.ey.com](mailto:jatinder.wadhwa@ca.ey.com)

Andrew Schaefer <sup>(1)</sup>  
Senior Vice President  
416 932 6244  
[andrew.schaefer@ca.ey.com](mailto:andrew.schaefer@ca.ey.com)

Martin Rosenthal  
Senior Vice President  
514 879 6549  
[martin.rosenthal@parthenon.ey.com](mailto:martin.rosenthal@parthenon.ey.com)

Martin Carrière  
Senior Vice President  
514 879 3254  
[martin.carriere@parthenon.ey.com](mailto:martin.carriere@parthenon.ey.com)

Copies of the SISP Order and the SISP procedures may be obtained from the website of the Monitor at [www.ey.com/ca/endoceutics](http://www.ey.com/ca/endoceutics).

(1) Any inquiries by U.S. persons should be directed to Ernst & Young Corporate Finance (Canada) Inc. through Andrew Schaefer.

### **About Endoceutics Group**

Established in Canada in 2006, Endoceutics Group is a vertically integrated biopharmaceutical company leveraging on over 40 years of research in the field of endocrinology and is supported by two distinct business units. The pharmaceutical research and development business of Endoceutics Group is focused on women's health and has commercialized Intrarosa™, a patent-protected product for treatment of vulvovaginal atrophy, in 19 countries and counting. Its wholly-owned subsidiary, MSH Pharma, an emerging CDMO with cGMP certifications from Health Canada, US FDA and EMEA, manufactures Intrarosa™ and is highly specialized in suppositories and suspension enema products with additional liquid manufacturing capabilities.

<https://endoceutics.com/en/>

<https://mshpharma.com/en/>